Literature DB >> 27653912

Maintenance immunosuppression in myasthenia gravis.

Lauren Gotterer1, Yuebing Li2.   

Abstract

Therapies for myasthenia gravis (MG) include symptomatic and immunosuppressive treatment. Options for immunosuppression include corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, rituximab, cyclophosphamide, intravenous immunoglobulin, plasmapheresis, and thymectomy. The practical aspects of long-term immunosuppressive therapy in MG will be critically reviewed in this article. Treatment for ocular and generalized myasthenia gravis will be discussed. Application of these therapies needs to be considered in conjunction with their efficacy, disease subtypes and severity, and patient co-morbidities.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corticosteroid; Immunosuppression; Intravenous immunoglobulin; Myasthenia gravis; Thymectomy

Mesh:

Substances:

Year:  2016        PMID: 27653912     DOI: 10.1016/j.jns.2016.08.057

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis.

Authors:  Yang Shumei; Li Yi; Meng Huanyu; Li Zhibin; Jin Wanlin; Xu Liqun; Yang Huan
Journal:  Eur J Clin Pharmacol       Date:  2019-02-07       Impact factor: 2.953

2.  Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

Authors:  Kaitlyn Koenig Thompson; Stella E Tsirka
Journal:  Handb Exp Pharmacol       Date:  2022

Review 3.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

4.  Strategies to reduce line infections in a small child with homozygous familial hypercholesterolaemia who cannot yet receive LDL apheresis.

Authors:  Misan Lee; Janet Barr; Stewart Kribs; Guido Filler
Journal:  BMJ Case Rep       Date:  2017-09-01

Review 5.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

6.  Chinese Herbal Medicine for Myasthenia Gravis: A Systematic Review and Meta-Analysis.

Authors:  Shuang Chen; Meng-Bei Xu; Xiao-Li Zhou; Pei-Qing Rong; Ting-Yu Jin; Guo-Qing Zheng
Journal:  Front Pharmacol       Date:  2018-08-30       Impact factor: 5.810

7.  A critical reflection on our first patient presenting with Anti-Nmethyl- D-aspartate receptor encephalitis.

Authors:  Susanne Buechner; Igor Florio; Gabriele J Sixt; Francesco Teatini
Journal:  Neurol Int       Date:  2019-09-18

8.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.

Authors:  Josep Gamez; María Salvadó; Francesc Carmona; Miriam de Nadal; Laura Romero; Daniel Ruiz; Alberto Jáuregui; Olga Martínez; Javier Pérez; Pilar Suñé; María Deu
Journal:  Ther Adv Neurol Disord       Date:  2019-07-17       Impact factor: 6.570

9.  Independent long-term result of robotic thymectomy for myasthenia gravis, a single center experience.

Authors:  Dong-Tao Yin; Ling Huang; Bing Han; Xiu Chen; Shi-Min Yin; Wen Zhou; Jian Chu; Tao Liang; Tian-Yang Yun; Yang Liu
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 10.  Treatment strategies for autoimmune encephalitis.

Authors:  Yong-Won Shin; Soon-Tae Lee; Kyung-Il Park; Keun-Hwa Jung; Ki-Young Jung; Sang Kun Lee; Kon Chu
Journal:  Ther Adv Neurol Disord       Date:  2017-08-16       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.